Sharma, A.; Mehra, V.; Kumar, V.; Prakash, H. Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases. Preprints2023, 2023121509. https://doi.org/10.20944/preprints202312.1509.v1
APA Style
Sharma, A., Mehra, V., Kumar, V., & Prakash, H. (2023). Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases. Preprints. https://doi.org/10.20944/preprints202312.1509.v1
Chicago/Turabian Style
Sharma, A., Vijay Kumar and Hridayesh Prakash. 2023 "Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases" Preprints. https://doi.org/10.20944/preprints202312.1509.v1
Abstract
Neurodegenerative diseases like Alzheimer's diseases are irreversible, progressive, and refractory in nature and managed very poorly. AD is manifested with the aggregation of unfolded proteins, synaptic pathology and dementia and poses challenges to the health care system globally. Only very few treatments with minimal effect are available to the patients and their caregivers. Despite numerous clinical trials which were launched for AD, unfortunately, most of them failed in satisfying the pharmacological criteria. At cellular levels, many signaling pathways have been proposed for the sterile / refractory behavior of degenerating neurons. Among those, Mitogen activated protein kinases (MAPKs) are the critical cellular networks which are involved in the development of Alzheimer’s disease. Several studies have demonstrated a favorable impact of MAPK inhibition on inflammatory programming, synaptic plasticity, and memory problems in mouse models of AD. In view of this, various clinical trials were launched with several MAPK inhibitors (with good safety profile and less side-effects) have yielded positive results in AD patients suggesting that MAPK targeting may be effective for reducing the pathogenesis of AD, but due to selectivity, dosing and patient stratification, this aspect still need development. In view of selectivity and off-target effects, only a few MAPK inhibitors have been employed in clinical trials against AD indicating a scope of development in this area. Therefore, this study focuses on MAPK based interventions as an upcoming and innovative approach for alleviating AD with special emphasis on clinical studies.
Medicine and Pharmacology, Neuroscience and Neurology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
